Not surprisingly, COVID-19 appears to have significantly impacted pituitary patients’ access to healthcare. Our brief survey elicited information from respondents on their experiences and attitudes towards obtaining healthcare via telemedicine. Dr. Blevins shares the findings
Important changes in telehealth visit regulations provide an excellent opportunity for patients to receive consultations from highly experienced specialists in pituitary disease. Read on! On Monday, November 16, 2020, doctors Lewis Blevins and Sandeep Kunwar
Telemedicine, how practices have adapted, views on pros and cons, and how things may change in the future.
From the desk of Lewis S Blevins Jr M.D. co-founder – As telemedicine expands, more and more health centers are providing this service to patients. In fact, during the week that we recorded this podcast,
From the desk of JD Faccinetti cofounder – This article on the Brazilian Medical Council recent decision to approve telemedicine services comes to us from Nathalia Kneipp in Brazil. The article was recently published in
Today we discuss the findings of the recently conducted patient survey on telemedicine. The survey shed some light on critical patient perspectives and perceptions, to help us arrive at some initial conclusions, and identify areas
Our telemedicine series continues with this podcasts on the results of our recent survey with physicians, primarily endocrinologists. In it, Dr. Lewis Blevins shares the results and explores physicians attitudes and perspectives. This is the
From the desk of Lewis S Blevins Jr. M.D. cofounder – Telemedicine is an emerging concept that provides unique opportunities in patient care and at the same time challenges the established framework and structure of
From Lewis S Blevins, Jr. M.D. – Long-term follow-up of patients with pituitary disorders is essential for many reasons. Firstly, those patients who have been rendered disease-free are always at risk for recurrence. While long-term
In our first live-talk session of 2023, we focus on critical topics, including insurance delay trends affecting pituitary medical practices, interesting clinical cases we can learn from, where telemedicine is going after the Covid era, and more commentary from the subjects we covered in our recent “briefing and insights” article.
This session presents more musing based on the actual practice of pituitary medicine, including growth hormone, the recent Covid-19 surge, dexamethasone dose adjustments, an interesting empty sella case with an enlarged pituitary gland, gadolinium, and the connection between mold and pituitary tumors misinformation flying around on the internet, adrenal and pituitary Cushing’s, and a look at telemedicine changes that may not be that good for patients.
Has COVID-19 affected you or not? What narrative will you construct as time moves forward resulting from the events of recent years? Pausing to examine what you choose to derive is up to each person, but it is essential to know that the more a person decides to choose rather than allow the choice to be made for them, the more they can move forward and beyond. Having lived through a worldwide pandemic means we have all not only survived, but we’ve endured.